{"PubmedArticle": [{"MedlineCitation": {"InvestigatorList": [], "SpaceFlightMission": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "OtherID": [], "PMID": "17926488", "DateCompleted": {"Year": "2007", "Month": "11", "Day": "13"}, "DateRevised": {"Year": "2015", "Month": "11", "Day": "19"}, "Article": {"Language": ["rus"], "ELocationID": [], "ArticleDate": [], "Journal": {"ISSN": "0023-2149", "JournalIssue": {"Volume": "85", "Issue": "8", "PubDate": {"Year": "2007"}}, "Title": "Klinicheskaia meditsina", "ISOAbbreviation": "Klin Med (Mosk)"}, "ArticleTitle": "[Correction of ventricular late potentials with drug and non-drug methods in patients with essential hypertension].", "Pagination": {"StartPage": "37", "EndPage": "40", "MedlinePgn": "37-40"}, "Abstract": {"AbstractText": ["The aim of the work was to evaluate the effects of drug and non-drug methods of treatment of patients with essential hypertension (EH) on ventricular late potentials (VLP). One hundred and thirteen patients with I to II stage EH aged 30 to 73 (mean age 53 +/- 9.7 years) were included in the study. VLP were registered by recording signal-averaged ECG (SA-ECG) before and after treatment with antihypertensive preparations (lisinopril, nifedipine) and intravenous ozone therapy. VLP were detected in 34 (30%) of the EH patients. The study found a decrease in the frequency of VLP detection from 40% (8 patients) to 10% (2 patients) after therapy with the ACE inhibitor lisinopril. In the group of patients who received monotherapy with the calcium antagonist nifedipine the number of subjects with VLP before and after the treatment was the same, 3 patients or 20%. In the group receiving bi-component therapy with lisinopril, an ACE inhibitor, and nifedipine, a calcium antagonist, the number of patients with VLP fell from 4 subjects (28.6%) to 1 subject. These data were confirmed with significant SA-ECG parameters. The study also revealed that ozone therapy as a part of complex treatment of EH improved SA-ECG parameters, which manifested by a decrease in VLP from 29.7% to 14.1%."]}, "AuthorList": [{"AffiliationInfo": [], "Identifier": [], "LastName": "Gimaev", "ForeName": "R Kh", "Initials": "RKh"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Rukhov", "ForeName": "V I", "Initials": "VI"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Drapova", "ForeName": "D P", "Initials": "DP"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Razin", "ForeName": "V A", "Initials": "VA"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Iudina", "ForeName": "E E", "Initials": "EE"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Auadi", "ForeName": "Kh B", "Initials": "KhB"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Sharangin", "ForeName": "S A", "Initials": "SA"}], "PublicationTypeList": ["English Abstract", "Journal Article"]}, "MedlineJournalInfo": {"Country": "Russia (Federation)", "MedlineTA": "Klin Med (Mosk)", "NlmUniqueID": "2985204R", "ISSNLinking": "0023-2149"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Angiotensin-Converting Enzyme Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Calcium Channel Blockers"}, {"RegistryNumber": "0", "NameOfSubstance": "Delayed-Action Preparations"}, {"RegistryNumber": "451W47IQ8X", "NameOfSubstance": "Sodium Chloride"}, {"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}, {"RegistryNumber": "E7199S1YWR", "NameOfSubstance": "Lisinopril"}, {"RegistryNumber": "I9ZF7L6G2L", "NameOfSubstance": "Nifedipine"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": [], "DescriptorName": "Aged"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Angiotensin-Converting Enzyme Inhibitors"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Calcium Channel Blockers"}, {"QualifierName": [], "DescriptorName": "Delayed-Action Preparations"}, {"QualifierName": [], "DescriptorName": "Drug Therapy, Combination"}, {"QualifierName": [], "DescriptorName": "Electrocardiography"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["diagnosis", "epidemiology", "physiopathology"], "DescriptorName": "Hypertension"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Lisinopril"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Nifedipine"}, {"QualifierName": ["metabolism"], "DescriptorName": "Ozone"}, {"QualifierName": ["metabolism", "therapeutic use"], "DescriptorName": "Sodium Chloride"}, {"QualifierName": ["drug therapy", "epidemiology", "therapy"], "DescriptorName": "Ventricular Dysfunction"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2007", "Month": "10", "Day": "12", "Hour": "9", "Minute": "0"}, {"Year": "2007", "Month": "11", "Day": "14", "Hour": "9", "Minute": "0"}, {"Year": "2007", "Month": "10", "Day": "12", "Hour": "9", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["17926488"]}}], "PubmedBookArticle": []}